SUMMARY
This year’s conference was organised in San Francisco from 23 till 25 January 2025, again as a hybrid event. Pan-RAS inhibition shows early, deep molecular responses in RAS-mutant pancreatic adenocarcinoma and looks very promising regarding PFS and OS in a phase 1 study. Adjuvant treatment with aspirin daily for three years reduced the recurrence rate in colorectal cancer patients with somatic alterations in the PI3K signalling pathway. Two other top stories of ASCO GI 2025 are nivolumab + ipilimumab beating nivolumab monotherapy across treatment lines in MSI-high/deficient mismatch repair (MMR) metastatic colorectal cancer and encorafenib + cetuximab + mFOLFOX6 as the new standard of care for first-line treatment of BRAF V600E-mutant colorectal cancer. The prognostic role of circulating tumour DNA (ctDNA) in colorectal cancer stage II-III is consistent between different trials and under active investigation in randomised trials. The combination of everolimus and lanreotide significantly prolonged progression-free survival compared to everolimus monotherapy as first-line treatment for grade 1 or 2 gastroenteropancreatic neuroendocrine tumours with poor prognostic features. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(BELG J MED ONCOL 2025;19(3): 114–128)